Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale-Reference-Cited by-同舟云学术

Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale

Published:2022-10-01 Issue:10 Volume:38 Page:774-778
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Kouamou Vinie¹^ORCID,Machekano Rhoderick²,Mapangisana Tichaona²,Maposhere Caroline³,Munyati Shungu³,Mutsvangwa Junior³,Shamu Tinei⁴⁵⁶^ORCID,McCarty Kathy⁷,Katzenstein David³,Manasa Justen⁸⁹

Affiliation:

1. Unit of Internal Medicine, University of Zimbabwe, Harare, Zimbabwe.

2. Department of Medicine, University of Stellenbosch, Cape Town, South Africa.

3. Department of Molecular Biology, Biomedical Research and Training Institute, Harare, Zimbabwe.

4. Newlands Clinic, Harare, Zimbabwe.

5. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

6. Graduate School of Health Sciences, University of Bern, Bern, Switzerland.

7. Chidamoyo Christian Hospital, Karoi, Zimbabwe.

8. Department of Laboratory Medicine and Investigative Sciences, University of Zimbabwe, Harare, Zimbabwe.

9. African Institute for Biomedical Sciences and Technology, Harare, Zimbabwe.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2021.0140

Reference24 articles.

1. 1. World Health Organization. Guidelines on the Public Health Response to Pre-treatment HIV Drug Resistance. Switzerland; 2017.

2. 2. World Health Organization. Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Switzerland; 2018.

3. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

4. 4. Underwood M, DeAnda F, Dorey D, et al. Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naive Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762). 13th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. Barcelona, Spain; 2015.

5. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of dolutegravir on ferritin, iron, and C-reactive protein among people living with HIV and co-infections;Southern African Journal of HIV Medicine;2024-04-30

2. Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia;Integrated Pharmacy Research and Practice;2024-04

3. Histomorphometric changes in testis following administration of tenofovir nanoparticles in an animal model;Discover Nano;2024-03-25

4. Strengthening and enhancing national antiretroviral drug resistance surveillance in Zimbabwe—A country that has reached UNAIDS 95-95-95 amongst adults;Frontiers in Public Health;2024-02-14

5. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe;AIDS;2024-01-16